Panelists discuss how collaboration between pathologists, oncologists, and pulmonologists is essential for timely next-generation sequencing (NGS) testing in early-stage non–small cell lung cancer (NSCLC), emphasizing that molecular testing should ideally be ordered at diagnosis with prioritization of EGFR, ALK, ROS1, BRAF, MET, KRAS, RET, and NTRK biomarkers to guide treatment decisions before surgical intervention.
2 weeks Ago Video content above is prompted by the following: NGS Testing in NSCLC: Workflow Summary for Physicians Testing Workflow and Team Collaboration Optimal Timing for Molecular Testing Prioritized Biomarkers in Early-Stage NSCLC Recommendations Consider liquid biopsy when tissue is insufficient or to complement tissue testing.
Gas prices can vary quite a bit from state to state, but one...
